Navigation Links
Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Date:12/15/2009

SI). Delafloxacin successfully completed two additional Phase 2 trials with the oral formulation. In microbiological tests of large numbers of contemporary clinical isolates of quinolone resistant MRSA, delafloxacin has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin. Delafloxacin also has been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic, and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic areas.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company currently has two drug candidates: delafloxacin, which is ready to enter Phase 3 clinical trials, and radezolid, whose oral form has been tested for safety and efficacy in two Phase 2 trials. Delafloxacin is a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA). Radezolid, a new oxazolidione discovered by Rib-X using its structure-based drug design approach, is an oral/IV agent for the treatment of serious multi-drug-resistant infections. The Company also has two other structure-based discovery programs, Rx-04 and Rx-02. The Rch-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria. The Rx-02 discovery program is focused on developing an IV/oral macrolide active against MRSA, multidrug-resistant Streptococcus pneumoniae, and S. pyogenes. Rib-X's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many know
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
2. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
3. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
7. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
8. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
9. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
10. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
11. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Israel Brain ... 2013 , Israel,s 1 st ... 14 th -15 th in Tel Aviv ... innovative city in the world by the Wall Street ... BrainTech Israel 2013 will showcase the latest breakthroughs in ...
(Date:5/23/2013)... , May 23, 2013 EarlySense, ... today that the prize for ,Best Novel Idea, at ... Medical Emergency Teams International Conference, hosted this year in ... awarded to a clinical research team studying the impact ... Hospital in Los Angeles . The ...
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3
(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
(Date:5/23/2013)... PA (PRWEB) May 23, 2013 ... Teaching Site, offering a comprehensive babysitting training course for ... program was developed by Indianapolis pediatrician Dr. Patricia Keener ... the care of an adult sitter who didn’t know ... well-rounded youth development program with a medical basis that ...
(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...
Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth ... antibiotics technologies , Offer an analysis of antibiotics resistance ...
... , WEDNESDAY, Dec. 2 (HealthDay News) -- In the ... patients in the United States have improved modestly, a ... more than 100,000 patients diagnosed with stage 4 non-small ... patient information was in the U.S. National Cancer Institute,s ...
... have metabolic syndrome, study finds , WEDNESDAY, Dec. 2 ... overweight college football players from being at higher risk ... disease, a new study suggests. , Researchers studied linemen ... obese. Of those, 42 percent had metabolic syndrome, a ...
... Va., Dec. 2 By now, most people have heard of ... the latest product on the market is now available at the ... at the amazingly low price of $14.99. , "This new product ... very low price, before making a bigger investment in a smokeless ...
... MONTREAL, Dec. 2 /PRNewswire/ - As part of its continued ... part of Pfizer, has pledged more than 40 million international ... Hemophilia (WFH). This is the largest donation ever made to ... impact to advance the WFH,s goals. , "This donation will ...
... , KNOXVILLE, Tenn., Dec. 2 TeamHealth ( www.teamhealth.com ... of Naples-based Emergency Physicians of Naples, LLC (EPN). Since ... Healthcare System to staff the emergency facilities at the Downtown ... EPN also provides the staffing for two stand-alone urgent care ...
Cached Medicine News:Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:Gains Made in Lung Cancer Survival 2Health News:Oversized College Football Players May Face Heart Risks 2Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2
... Ultra Strep A Test is a color ... DLT uses antibody labeled color particles coated ... device. DLT allows greater sensitivity than the ... In the test procedure, a throat swab ...
... Fertell test is an easy to use, one ... reserve by means of determining the amount of ... sample. The test is performed two days after ... menstrual cycle) and is similar in design and ...
... The Cholestech GDX System delivers an unmatched combination ... ideal solution for assessing and monitoring a patient's ... demo, click here ., ,The CLIA-waived Cholestech ... A1C results in less than 5 minutes. The ...
... The Cholestech LDX System, using patented, ... plus glucose and ALT in only 5 ... new ALT test, you can get immediate ... measurement capabilities is not the only advantage ...
Medicine Products: